NCT06483906 2026-03-03
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05906914 2026-02-04
CHA
First Affiliated Hospital of Zhejiang University
Phase 2 Completed
NCT06221683 2024-08-22
GMCAII
Children's Hospital of Soochow University
Phase 2 Recruiting
NCT04248595 2022-09-08
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Zhongda Hospital
Phase 2 Unknown
NCT03135054 2020-12-10
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
The University of Hong Kong
Phase 2 Unknown
NCT03170895 2020-03-30
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
The University of Hong Kong
Phase 2 Completed
NCT01873495 2019-09-24
Omacetaxine for Consolidation and Maintenance
Emory University
Phase 2 Terminated
NCT01272245 2018-05-30
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02029417 2016-05-09
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 2 Terminated